The 2011 Chevrolet Fireball Run Adventurally announces a first-of-its-kind program…
Named a leader in transforming how business, society function
Wilmington, NC (Profitable.com) Pharmaceutical Product Development, LLC (PPD) today announced the Computerworld Honors Program has named PPD a 2013 Laureate. The annual awards celebrate visionary applications of information technology (IT) that promote positive social, economic and educational change.
“We are pleased to be recognized for PPD’s commitment to unleashing innovative technology to help engage patients in their health care and advance medical research,” said Mike Wilkinson, PPD’s chief information officer and executive vice president. “To develop the critical therapies needed in an evolving health care environment, biopharmaceutical companies need research partners that provide advanced IT solutions. PPD combines cutting-edge IT solutions with streamlined process improvement, real time analytics and customizable training to engage patients and solve biopharmaceutical industry challenges.”
PPD was recognized for its suite of technologies that support patients’ involvement, education and awareness regarding their health care. PPD PatientView is an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient communication, compliance, retention and satisfaction in clinical trials. Using social media, PPD PatientPoint helps people interested in participating in a trial connect with a doctor working on the trial, ultimately advancing enrollment and maximizing effective patient recruitment efforts. PPD’s Clinical Trials Mobile App provides patients with easy access to search a database of available clinical trials worldwide, find studies matching specified categories and keywords, and view detailed information about specific clinical trials.
“Technology continues to play a pivotal role in transforming how business and society function,” said Computerworld’s Julia King, executive editor, events. “For the past 25 years, the Computerworld Honors Program has had the privilege of celebrating innovative IT achievements and is honored to recognize the outstanding accomplishments of the 2013 class of laureates. Their technologies demonstrate how IT can advance an organization’s ability to compete, innovate, communicate and prosper.”
To select this year’s laureates, Computerworld relied on a panel of judges to evaluate the humanitarian benefits and measurable results of applying technology to meet a specific social or business need. PPD accepted the Laureate award during a ceremony held June 3 in Washington, D.C.
Founded by International Data Group in 1988, the Computerworld Honors Program recognizes organizations and individuals using IT to promote and advance public welfare, benefit society and business and change the world for the better. Computerworld is a leading source of technology news and information for IT influencers, providing peer perspective, IT leadership and business results.
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’sComputerworld Honors Laureate award, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services less competitive; competition in the outsourcing industry; the ability to attract, integrate and retain key personnel; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.